Some eligible Amazon customers have just 30 days left to file a claim in the company's $2.5 billion settlement with the Federal Trade Commission. While not all Amazon customers are eligible, those who ...

GLP-1 receptor agonists (GLP-1 RAs) are associated with reduced incidence of breast cancer among women with overweight or obesity, according to two observational studies. One found that GLP-1 RA users ...

A new lawsuit filed by the U.S. Federal Trade Commission (FTC) is a showcase of how hard it’s become to police the app stores for scammy apps. The suit alleges that a company known as Genesis Tech ...

June 8 (Reuters) - Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is not a cause for alarm, a large new data analysis ...

Off-label use of medications like Ozempic, Wegovy, Mounjaro, and Zepbound is becoming increasingly common to address weight management, insulin resistance, and diabetes related complications in type 1 ...

Critics hope to keep Elon Musk from escaping a strict data-privacy order imposed by the Federal Trade Commission (FTC) shortly before he took over Twitter. The FTC order placed restrictions on X’s ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

June 3 (Reuters) - A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen ...

A massive study of more than 600,000 U.S. veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight loss—they could also fight addiction itself.

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not ...